When Will Citius Oncology, Inc. (NASDAQ:CTOR) Become Profitable? [Yahoo! Finance]
Citius Oncology, Inc. (CTOR)
Company Research
Source: Yahoo! Finance
Citius Oncology, Inc. focuses on the development and commercialization of innovative targeted oncology therapies. With the latest financial year loss of US$21m and a trailing-twelve-month loss of US$27m, the US$131m market-cap company amplified its loss by moving further away from its breakeven target. The most pressing concern for investors is Citius Oncology's path to profitability – when will it breakeven? In this article, we will touch on the expectations for the company's growth and when analysts expect it to become profitable. This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality. Citius Oncology is bordering on breakeven, according to some American Biotechs analysts. They anticipate the company to incur a final loss in 2026, before generating positive profits of US$61m in 2027. So, the company is predicted to breakeven approximately 2 years from today. How fast will the company have to grow each year in order to reac
Show less
Read more
Impact Snapshot
Event Time:
CTOR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CTOR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CTOR alerts
High impacting Citius Oncology, Inc. news events
Weekly update
A roundup of the hottest topics
CTOR
News
- Citius Oncology Expands LYMPHIR™ Distribution to Turkey and Middle East Countries Through Exclusive Agreement with Er-KimPR Newswire
- Citius Oncology Announces U.S. Commercial Launch of LYMPHIR™, a Novel Cancer Immunotherapy for Cutaneous T-Cell Lymphoma (CTCL) [Yahoo! Finance]Yahoo! Finance
- Citius Oncology Announces U.S. Commercial Launch of LYMPHIR™, a Novel Cancer Immunotherapy for Cutaneous T-Cell Lymphoma (CTCL)PR Newswire
- Citius Oncology to Exhibit at the 67th American Society of Hematology (ASH) Annual Meeting [Yahoo! Finance]Yahoo! Finance
- Citius Oncology to Exhibit at the 67th American Society of Hematology (ASH) Annual MeetingPR Newswire
CTOR
Sec Filings
- 12/1/25 - Form 8-K
- 12/1/25 - Form 4/A
- 12/1/25 - Form 4/A
- CTOR's page on the SEC website